INDIA'S rules on localisation of data and price caps on medical devices imported from the US are barriers to trade but New Delhi is committed to addressing them after the country's elections, US commerce secretary Wilbur Ross said on Tuesday (7).
Speaking at a business conference in New Delhi, Ross said there were still overly restrictive market barriers in India. The US is India's second-biggest trade partner after China.
"We applaud India's commitment to addressing some of these barriers once the government is re-formed, probably starting in the month of June," Ross said in a speech.
India's 39-day general election ends on May 19, and votes will be counted four days later.
Ross met his Indian counterpart Suresh Prabhu on yesterday (6), after which New Delhi said that the two countries would engage regularly to resolve outstanding trade issues.
India and the US are locked in disputes over tariffs, price caps India has imposed on imported US medical devices, and rules banning companies from selling products via firms in which they have an equity interest.
Ross said India's recent push to force foreign companies to store more of their user data locally was a hindrance to trade.
"Our role is to eliminate barriers to US companies operating here, including, data localisation restrictions that actually weaken data security and increase the cost of doing business," he said.
Last year, global payments companies including Mastercard, Visa, and American Express unsuccessfully lobbied India to relax central bank rules requiring all payment data on domestic transactions to be stored locally.
Ross said India's 2017 decision to cap prices of medical devices made in the US was also an issue.
US president Donald Trump announced in March that he would end preferential trade treatment for India that allows duty-free entry for up to $5.6 billion worth of its exports to the US.
"As President Trump has said, trade relationships should be based and must be based on fairness and reciprocity. But currently, US businesses face significant market access barriers in India," Ross said.
"These include both tariff and non-tariff barriers as well as multiple practices and regulations that disadvantage foreign companies."
US goods and services trade with India totalled an estimated $142.1bn in 2018, with the US running a deficit of $24.2bn.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.